Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene

CE/BZA significantly improved overall and vasomotor-related MSQOL across populations of postmenopausal women with varying baseline symptom statuses. Women with greater menopausal symptoms at baseline were more likely to experience clinically meaningful changes.